Immunoprecise Antibodies Ltd reports results for the quarter ended October 31 - Earnings Summary

• Immunoprecise Antibodies Ltd IPA.OQ reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended October 31, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of two analysts for the quarter was for a loss of 9 cents per share. Wall Street expected results to range from -12 cents to -7 cents per share.

• Revenue fell 0.4% to C$6.13 million from a year ago; analysts expected C$6.44 million.

• Immunoprecise Antibodies Ltd's reported EPS for the quarter was a loss of 9 cents​.

• The company reported a quarterly loss of C$2.55 million.

• Immunoprecise Antibodies Ltd shares had fallen by 34.3% this quarter and lost 75.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 26.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $6.00

This summary was machine generated from LSEG data December 10 at 02:31 p.m. UTC. ​All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)